Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03036098 · ClinicalTrials.gov registry record · Phase 3
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
A Phase 3 study of Urothelial Cancer, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 1,314
- Enrollment target
- 20
- Study locations
NCT03036098 is a Phase 3 study of Urothelial Cancer that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 1,314 participants, above the 522-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (152% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT03036098, a Phase 3 study of Urothelial Cancer, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,314 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously untreated inoperable or metastatic urothelial cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Gemcitabine
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
Study Locations (20)
Massachusetts
- Local Institution - 0056 - Boston
- Local Institution - 0073 - Boston
- Local Institution - 0208 - Boston
- Local Institution - 0207 - Milford
Florida
- Local Institution - 0051 - Boca Raton
- Local Institution - 0087 - Fort Lauderdale
- Local Institution - 0062 - Jacksonville
California
- Local Institution - 0115 - Fresno
- St Joseph Heritage Healthcare - Santa Rosa
Georgia
- Local Institution - 0004 - Athens
- Local Institution - 0033 - Thomasville
Missouri
- Local Institution - 0032 - Kansas City
- Local Institution - 0095 - St Louis
Alaska
- Local Institution - 0001 - Anchorage
Illinois
- Local Institution - 0046 - Chicago
Louisiana
- Local Institution - 0117 - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,314 participants |
| Start Date | 2017-03-24 |
| Est. Completion | 2026-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03036098
The ClinicalTrials.gov registry entry for NCT03036098 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,314 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 522-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (152% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03036098 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Massachusetts, Florida, California.
Frequently Asked Questions
What is clinical trial NCT03036098 about?
NCT03036098 is a clinical study titled "Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer". The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously untreated inoperable or...
What is the current status of trial NCT03036098?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,314 participants. The study started on 2017-03-24. Estimated completion is 2026-05-15.
What conditions does trial NCT03036098 study?
This clinical trial studies the following conditions: Urothelial Cancer.
What interventions are being tested in trial NCT03036098?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03036098?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03036098 being conducted?
This trial has 20 study locations across Alaska, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
ACTIVE NOT RECRUITING · Phase 3
-
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
ACTIVE NOT RECRUITING · Phase 3
-
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
COMPLETED · Phase 3
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.